Skip to main content
      Rheumatic diseases are highly affected by environmental impacts

      Appreciate the ACR for creating a Climate Change Task F

      Eric Dein ericdeinmd

      10 months ago
      Rheumatic diseases are highly affected by environmental impacts Appreciate the ACR for creating a Climate Change Task Force to proactively and reactively respond to the issues this creates for rheumatologist @ACRheum @dddesir #ACR24 @RheumNow https://t.co/h4jCMa9Fyg
      CV risk after gout attack

      1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly

      Eric Dein ericdeinmd

      10 months ago
      CV risk after gout attack 1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance) @RheumNow #ACR24 year in review Pillinger https://t.co/a2zS8mIw3L
      Year in review: Can #gout flares increase CV risk?
      Cipoletta et al - pts with gout may be at inc risk of CV events for

      sheila RHEUMarampa

      10 months ago
      Year in review: Can #gout flares increase CV risk? Cipoletta et al - pts with gout may be at inc risk of CV events for at least 30-120 days after flares. Emphasize CV risk mgt in all patients w/ gout. @RheumNow #ACR24 https://t.co/p1aXVgqkuR
      Knee OA
      Krill oil - No benefit in randomized PBO control study
      MTX (25 mg) for pain - modest diff in pain (numerical, no

      Eric Dein ericdeinmd

      10 months ago
      Knee OA Krill oil - No benefit in randomized PBO control study MTX (25 mg) for pain - modest diff in pain (numerical, not WOMAC), lost by 12 mo STEP-9: GLP1 agonist for BMI>30 w knee OA. 60% better than PBO. Wt or other benefits? @RheumNow Michael Pillinger #ACR24 year in review https://t.co/dMw4T0tWLX
      Year in review:
      Semaglutide reduced knee pain over 68 weeks in patients with high BMI and moderate knee #osteoarthritis

      sheila RHEUMarampa

      10 months ago
      Year in review: Semaglutide reduced knee pain over 68 weeks in patients with high BMI and moderate knee #osteoarthritis pain But mechanism of knee pain improvement not yet known if due to wgt loss or other mechanisms. @Rheumnow #ACR24 @rheumarhyme @theactiverheum https://t.co/PkrcIMbgPl
      Abatacept for GPA?

      Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (backgr

      Brian Jaros, MD Dr_Brian_MD

      10 months ago
      Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7
      RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by

      Dr. John Cush RheumNow

      10 months ago
      RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
      Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
      ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
      A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
      Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t

      Antoni Chan MD (Prof) synovialjoints

      10 months ago
      Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY
      RA pearls from #ACR24 review course:
      1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
      2. Multimorbid

      Adela Castro AdelaCastro222

      10 months ago
      RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
      Myths by Daniel Clauw

      Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy

      Fibromyalgia is

      Eric Dein ericdeinmd

      10 months ago
      Myths by Daniel Clauw Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently #ACR24 Review Course @RheumNow https://t.co/JLyfnfMBML
      Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24

      TheDaoIndex KDAO2011

      10 months ago
      Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24 #ACRReview https://t.co/LJvrdVG1jg
      ×